Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Arcellx Inc.

    NASDAQ: ACLX · Real-Time Price · USD
    68.15
    1.90 (2.87%)
    At close: Jun 06, 2025, 3:59 PM
    68.10
    -0.07%
    After-hours: Jun 06, 2025, 04:59 PM EDT
    2.87%
    Bid 67.35
    Market Cap 3.76B
    Revenue (ttm) 76.81M
    Net Income (ttm) -162.42M
    EPS (ttm) -2.99
    PE Ratio (ttm) -22.79
    Forward PE -19.62
    Analyst Buy
    Ask 70
    Volume 467,705
    Avg. Volume (20D) 776,376
    Open 67.42
    Previous Close 66.25
    Day's Range 64.88 - 68.83
    52-Week Range 47.86 - 107.37
    Beta 0.28

    About ACLX

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol ACLX
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for ACLX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    7 months ago
    +0.79%
    Acrellx shares are trading lower after the company... Unlock content with Pro Subscription
    10 months ago
    +12.31%
    Arcellx shares are trading higher after the company reported better-than-expected Q2 financial results.
    news image

    2 weeks ago · businesswire.com

    Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025

    REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and...

    news image

    3 weeks ago · businesswire.com

    Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma

    REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and...

    news image

    1 month ago · zacks.com

    Arcellx, Inc. (ACLX) Reports Q1 Loss, Lags Revenue Estimates

    Arcellx, Inc. (ACLX) came out with a quarterly loss of $1.13 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.14 per share a year ago.

    news image

    1 month ago · seekingalpha.com

    Baron Health Care Fund Q1 2025 Top Net Purchases And Sales

    Initiated positions in Waters Corporation, Penumbra, McKesson, Masimo, and added to UnitedHealth Group due to strong market positions and growth potential. Waters Corporation's growth driven by biopha...

    news image

    1 month ago · seekingalpha.com

    Baron Health Care Fund Q1 2025 Top Contributors And Detractors

    Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals sa...

    news image

    2 months ago · businesswire.com

    Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors

    REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and...

    news image

    2 months ago · seekingalpha.com

    Arcellx Impressive Safety Data Leaves Doubts

    Arcellx's innovative cell therapy platform shows promising potential in treating multiple myeloma, a significant unmet medical need. Strong clinical trial results and strategic partnerships bolster co...

    Add to Watchlist